key: cord-0832112-20p8q8yz authors: Rashid, Sarem; Tsao, Hensin title: Effect of the COVID-19 Pandemic on Delayed Skin Cancer Services date: 2021-05-28 journal: Dermatol Clin DOI: 10.1016/j.det.2021.05.015 sha: 0036b6dcaf0b2e8525c912b1432c0db2ff440444 doc_id: 832112 cord_uid: 20p8q8yz The COVID-19 pandemic has presented a unique set of challenges and lessons to cancer care centers around the world. During this unprecedented time, dermatologists have been pressed to balance early surgical interventions for skin cancer with the risk of COVID-19 transmission. Here, we aim to summarize evidenced-based recommendations for the surgical management and prioritization of three skin cancer categories (cutaneous melanoma, keratinocyte cancer, and Merkel cell carcinoma) during the COVID-19 pandemic. Wide local excision (WLE) remains the mainstay treatment for early and localized lesions. Current guidelines recommend 1 cm margins for melanomas ≤2 mm, and 2 cm margins for thicker lesions >2 mm 21 . In the absence of delays, complete surgical excision should be performed 4-6 weeks after the initial diagnosis. Mohs surgery is utilized for melanomas with poorly distinguished visible margins (i.e. lentigo maligna melanoma and acral melanoma), including those in cosmetically-sensitive areas 22 . Appropriate intervals for melanoma time to definitive surgery (TDS) have been widely studied although lacks consensus 23 . A 2020 literature review of surgical delay and mortality in primary cutaneous melanoma yielded 5 total studies that addressed surgical delays of 1 month or longer 24 . From this sample, only 2 studies reported an association between delayed WLE and poor survival outcomes, both of which derived samples from the National Cancer Database increase in overall survival for TDS intervals less than 60 days, compared to after 60 days 26 . According to the NCCN, surgical treatment of T0 (melanoma in-situ or MIS) and T1 melanomas could have been delayed during pandemic surges for up to 3 months, with priority given to T3 and T4 melanomas 14 . If a substantial proportion of residual lesion remained after biopsy for T1 melanomas, then a complete biopsy with narrow surgical margins or elliptical excision with 1 cm surgical margins was recommended. In the setting of limited OR capacity, SLNB for lesions >0.8 mm were recommended deferral for up to 3 months. For melanomas staged N1 and above, the NCCN recommended deferral of lymphadenectomy if regional lymph nodes were palpable. Likewise, the BAD and BSDS suggested deferral of WLE for stage T0 and J o u r n a l P r e -p r o o f T1a melanomas based on histopathological features of the biopsy 11 . The ACMS suggested deferral of MIS for up to 2-3 months, and reiterated NCCN guidelines for management of T0 and T1a melanomas 12 . The ESMO endorsed a tiered system (high, high/medium, low) for guidelines based on value-based prioritization 27 . High priority surgeries included any curative resection for stage III lesions, procedures associated with neo-adjuvant trials. High/medium priority surgeries included WLE and SLNB for new invasive melanomas staged T1b or higher, WLE alone for T1a or lower tumors, and resection of oligometastatic disease. There were no surgeries designated in the low priority category. Lastly, the SSO endorsed a case-by-case evaluation of melanomas prior to surgery 28 . WLE for T0 melanomas could have been deferred for up to 3 months. Surgical treatment for T3 and T4 melanomas held priority over T1 and T2 melanomas, although gross complete resection recommended for any melanoma with a large degree of residual lesion present due to incomplete biopsy. SLNB should have been performed for lesions with >1 mm thickness and could otherwise be deferred for up to 3 months. The SSO guidelines included precise language to recommend documentation of tumor anatomic location in the event of surgical delay and encouraged that surgeries occur in the outpatient setting. Pandemic guidelines for all skin cancers are summarized in Table 1 . Keratinocyte cancers (KC), primarily comprised of basal cell carcinomas (BCC) and squamous cell carcinomas (SCC), represent the most common malignancy in fair-skinned populations 29 . Predisposing factors for KC's include chronic exposure to UV radiation, male gender, and an immunocompromised state. Risk of metastasis correlates to histological factors such as subtype (e.g. superficial, nodular, or infiltrative) and depth of the primary tumor 15,16 . J o u r n a l P r e -p r o o f Generally, BCC's are slow growing tumors that have a small estimated risk of metastasis (0.003-0.55%) 30 , whereas SCC's are fast-growing tumors with considerable likelihood to metastasize (0.5-16%) 31 . Primary management for KC includes WLE, electrodessication and curettage, and Mohs micrographic surgery. Mohs surgery has been shown to be the most effective treatment modality for high-risk or recurrent KC in some reports 17 . A meta-analysis of treatments used in KC reported an aggregated 5-year cure rate of 99% and 97% for previously untreated BCC and SCC, respectively 32 . A more recent prospective study from the Netherlands found no statistical difference in recurrence rates between surgical excision and Mohs surgery for treatment of Deferral of slowly-enlarging and well-differentiated SCC/SCC in-situ was also recommended, although no discrete time period is suggested. SCC that was symptomatic or contained significant risk factors such as rapid growth, poor differentiation, ulceration and perineural invasion should have been prioritized. The BAD and BSDS recommended deferring surgical J o u r n a l P r e -p r o o f excisions of BCC for 3-6 months unless the patient was highly-symptomatic or endorsed high potential for significant growth 11 . Surgical treatment for SCC/SCC in-situ that were small and well-differentiated may have also been reasonably deferred unless the lesion demonstrated rapid growth, poor differentiation, ulceration and/or perineural invasion. High-priority lesions should have been carefully evaluated on a case-by-case basis to assess the risks and benefits treatment with the concurrent risk of COVID-19 exposure. Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine-derived skin cancer that resides within the basal layer of the epidermis (e.g. deep skin and hair follicles) 34 . This lesion commonly affects individuals who are elderly (median age of diagnosis at 75-80 years) and immunocompromised 35, 36 . These underlying conditions have been associated with increased risk of requiring intensive care due to COVID-19 37 , thus extra precautions should be taken during treatment to limit potential exposure to the virus in this patient population. Treatment for MCC requires careful consideration of tumor stage and patient-specific factors. WLE with clear margins is performed to prevent local recurrence and regional metastasis of early stage tumors, although has not been shown effective in stand-alone-treatment 38, 39 . Mohs micrographic surgery has been recommended in order to effectively remove smaller lesions in cosmetically-sensitive areas, or to monitor local recurrence during adjuvant therapy 40 According to the NCCN, treatment should not have been deferred due to the COVID-19 pandemic because of high risk of disease progression 10 , with the exception of lesions <1 cm in elderly populations (favorable T1 tumors with no immunosuppression or angioinvasion) 42 . Delayed surgery of MCC may increase the likelihood that the patient requires adjuvant radiotherapy. In the setting of limited operating room capacity, sentinel lymph node biopsy (SLNB) could be deferred from wide local excision (WLE) or Mohs excision if the wound was allowed to granulate. NCCN guidelines also emphasized cutoffs in pathological stage to guide treatment. For example, MCC diagnosed at stage III (or above) should require careful evaluation of patient comorbidities by the physician to determine treatment (e.g. definitive resection with complete lymphadenectomy or off-label immunotherapy). The BAD and BSDS recommended prioritizing treatment for all "rapidly-enlarging tumors, poorly-differentiated tumors, perineural tumors, ulcerated and symptomatic lesions" in addition to careful multidisciplinary evaluation of complex cases 11 . Several clinical observations suggest that COVID-19 lockdown periods have caused disruptions in skin cancer care. There has been a substantial decrease in the number of skin cancers diagnosed [6] [7] [8] [9] 43, 44 , and treated 8, 9, 45 during lockdown ( Table 2 ). In the United Kingdom The COVID-19 pandemic has had a profound impact on the routine management of skin cancer services. Surgical delays in cancer have historically decreased long-term survival. Consequently, a significant reduction in skin cancer surgery may manifest as increased morbidity and mortality due to undetected tumors-although no outcomes during COVID-19 have been reported yet. Patients with high-risk underlying conditions such as old age, immunosuppression, and/or previous malignancy history should be carefully triaged by a multidisciplinary team to mitigate potential COVID-19 exposure. -When interpreting these guidelines, tumor-specific factors should be carefully examined in the context of patient history and pandemic status. -Guidelines for melanoma patients suggest deferral of melanoma in-situ for up to 2-3 months, with priority given to T1-T4 lesions. -A normal throughput of surgical and diagnostic processes for skin cancer should be maintained to avoid negative consequences associated with post-lockdown backlog. -When triaging cases during lockdown periods, the survival benefit for skin cancer surgery should outweigh the possible risk of COVID-related mortality. COVID-19: a look into the modern age pandemic Preserving Elective Surgeries in the COVID-19 Pandemic and the Future Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors Cancer Diagnostic Delay in Northern and Central Functional Fear Predicts Public Health Compliance in the COVID-19 Pandemic A significant reduction in the diagnosis of melanoma during the COVID-19 lockdown in a third Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic The effect of the COVID-19 pandemic on skin cancer surgery in the United Kingdom: a national, multi-centre, prospective cohort study and survey of Plastic Surgeons Management of melanoma patients during COVID-10. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: NMSC. National Comprehensive Cancer Network British Association of Dermatologists & British Society for Dermatological Surgery COVID-19: Skin cancer surgery guidance COVID-19 (Coronavirus) Preparedness. American College of Mohs Surgery European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment -Update National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Melanoma. National Comprehensive Cancer Network Histopathological characteristics of metastasizing squamous cell carcinoma of the skin and lips Basal cell carcinoma. Identification and treatment of the high-risk patient Melanoma of the Skin -Cancer Stat Facts Delayed melanoma diagnosis in the COVID-19 era: increased breslow thickness in primary melanomas seen after the COVID-19 lockdown Delay in Diagnosis and Treatment of Squamous Cell Carcinoma of the Skin Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma Current perspectives on Mohs micrographic surgery for melanoma Cutaneous Melanoma: Etiology and Therapy Surgical Delay and Mortality for Primary Cutaneous Melanoma Determination of the impact of melanoma surgical timing on survival using the National Cancer Database Effect of a delay in definitive surgery in melanoma on overall survival: A NCDB analysis ESMO management and treatment adapted recommendations in the COVID-19 era: Melanoma Resource for Management Options of Melanoma During COVID-19. Society of Surgical Oncology Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978-2012: empirical relationships Basal Cell Carcinoma With Pulmonary and Lymph Node Metastasis Causing Death Prognostic factors for metastasis in squamous cell carcinoma of the skin Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial Merkel cell carcinoma Incidence and survival for Merkel cell carcinoma in Queensland Merkel cell carcinoma incidence is increasing in Sweden COVID-19 and the elderly: insights into pathogenesis and clinical decision-making Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma Recurrence and Survival in Patients With Merkel Cell Carcinoma Undergoing Surgery Without Adjuvant Radiation Therapy to the Primary Site Mohs Micrographic Surgery for the Treatment of Merkel Cell Carcinoma Merkel cell carcinoma of the head and neck: A retrospective case series Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. Cancer The magnitude of COVID-19's effect on the timely management of melanoma and nonmelanoma skin cancers Reduction in skin cancer diagnoses in the UK during the COVID-19 pandemic